-
(IGXT)Mcap 28 M// Partnership THIS MONTH/1x Approved drug
IntelGenx (IGXT) Submits New Drug Application for Anti-Migraine VersaFilm(TM)
SAINT LAURENT, Quebec, March 27, 2013 (GLOBE NEWSWIRE) -- IntelGenx Corp. (IGX.V) (IGXT) ("IntelGenx" or the "Company"), a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
Forum Rules